

Emyria Receives Firm Commitments Of \$2.3M To Expand Clinical Services

HIGHLIGHTS

Firm bids received from new and existing sophisticated and professional investors for a placement of \$2.3m (before costs) at \$0.05 each together with 1 free attaching unquoted option for every 2 shares applied for ("Placement")

Director participation of \$320,000, with Chairman Greg Hutchinson subscribing for \$300,000 (subject to shareholder approval)

Funds to support the Empax Centre - dedicated to developing and delivering new mental health care programs and expected to drive potential revenues and clinical data collection. Funds to facilitate drug development and payer engagement across all programs.

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") delivering and developing new treatments for mental health and select neurological conditions, has secured firm bids of \$2.3M through a well supported Placement from new and sophisticated investors.

Use of Proceeds

Funds raised will support the strategic scale-up and national expansion of the Empax Centre (see ASX release 10 April 2024) Emyria's newly opened facility focussing on treatment and research to address significant unmet needs in mental health care, particularly for individuals struggling with treatment-resistant forms of PTSD - affecting nearly 500,000 Australians (<https://www.phoenixaustralia.org/news/ptsd-awareness-day-2022/>).

Strategic Expansion and Clinical Excellence

Funds are expected to enhance the Empax Centre's potential for revenues via clinical services and Sponsored research as well as Real-World Data collection. By the second half of FY25 the Centre is expected to achieve operational break-even, underscoring Emyria's commitment to clinical and commercial viability.

Additionally, funds to support further expansion of our treatment models both nationally and globally by securing and establishing additional sites to extend our reach and impact.

Innovation and Long-term Growth

The Placement will also support the Company's proprietary drug development initiatives. As part of our longer-term innovation pipeline, Emyria is advancing projects with strong IP in collaboration with esteemed global partners like the University of Western Australia and the NIH (See ASX release 28 February 2024). Backed by promising early preclinical results and a clear search report from the International Patent Examiner, these efforts aim to develop new, patentable treatments for PTSD and select neurological conditions, cementing our leadership in mental health innovation.

"We are embarking on an exciting phase of growth with our newly opened Empax Centre. I am profoundly optimistic about the impact our work will have on mental health and my commitment to cornerstoning this placement reflects my confidence in our innovative approach and the exceptional team leading our efforts to address the overwhelming challenges faced by those with treatment-resistant PTSD.

I am confident that the strategic use of these funds will significantly advance our mission, set new standards in care, and ultimately transform lives.

I am also deeply grateful for the significant support this placement has received, underscoring our shareholders' trust and belief in our mission to make significant strides in mental health care." **Greg Hutchinson, Chairman**



Details of the Placement:

The Placement comprises the issue of approximately 46,000,000 fully paid ordinary shares at \$0.05 each ("Placement Shares") representing a 12.28% discount to the last traded price as at 19 April 2024. In addition, the Placement includes 1 free attaching unquoted option for every 2 shares applied for and issued under the Placement ("Placement Options"). The Placement Options will be exercisable at \$0.10 each and expire 3 years from the date of issue.

The Placement Shares will be issued pursuant to the Company's placement capacity under ASX Listing Rules 7.1 and 7.1A. in the amounts of 2,937,061 and 36,662,939 respectively. The 19,800,000 Placement Options will be issued under ASX Listing Rules 7.1.

Chairman, Greg Hutchinson, provided a cornerstone investment of \$300,000 and Managing Director, Michael Winlo contributed \$20,000. The issue of 6,400,000 Placement Shares and 3,200,000 Placement Options to Messrs Hutchinson and Winlo is subject to the prior receipt of shareholder approval, which is planned to be sought at a general meeting expected to be held in June 2024 ("General Meeting").

Sixty Two Capital Pty Ltd acted as Lead Manager to the Placement. As partial consideration for Lead Manager services, the Company has agreed to issue up to 2,000,000 unquoted options to the Lead Manager (or its nominees) each exercisable at \$0.10 each and expiring 3 years from the date of issue ("Lead Manager Options"). Sixty Two Capital Pty Ltd has agreed to take its capital raising fee of 6% of total funds raised in shares and options at the same terms as the Placement, equating to 2,760,000 Shares and 1,380,000 unlisted options. The Lead Manager Options, Placement Shares and Placement Options will be issued under the Company's ASX Listing Rule 7.1 placement capacity.

Settlement of the first tranche of the Placement and issue of the new Shares and Options is expected to take place by Tuesday, 7 May 2024.

Emyria Limited is focused on developing and delivering new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and drug development:

generates

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD ¹

informs

Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and used to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia seeking new psychedelic-assisted therapies and treatments for neurological diseases as well as highly potent dose forms of Ultra-Pure CBD seeking registration for a range of mental health and neuroscience indications.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

This release has been approved by the Board of Emyria.

For further information, investment opportunities, or more about our approach to mental health treatment, please contact:

Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com

Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital

Corporate Advisor
Sufian Ahmad
+61 (0) 412 316 162
info@62capital.com.au